- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00403663
Effect of Body Mass Index on the Dose of Intrathecal Hyperbaric Bupivacaine for Elective Cesarean Section
Effect of Body Mass Index on the ED95 of Intrathecal Hyperbaric Bupivacaine for Elective Cesarean Section
Study Overview
Status
Intervention / Treatment
Detailed Description
Spinal anesthesia is the most common anesthetic technique used for Cesarean section. It offers many advantages over epidural and general anesthesia. However, one of the limitations of spinal anesthesia in Obstetrics is the use of a single shot technique as the continuous technique is associated with unacceptable incidence of PDPH. It is difficult to predict the exact level of sensory block because many factors affect the spread of local anesthetic injected into the CSF. Theoretically, obese patients may have greater intra-abdominal pressure, leading to compression of the inferior vena cava and engorgement of the epidural venous plexus, which in turn increases the pressure inside the epidural space. This augmented pressure is transmitted to the dural sac and diverge the CSF from the lumbosacral region, leading to a decrease in CSF volume. It has been demonstrated that the volume of CSF in lumbosacral region is an important factor affecting intrathecal spread of anesthetics.
Our hypothesis is that obese women require less intrathecal hyperbaric bupivacaine than do normal weight women to achieve satisfactory surgical anesthesia for elective Cesarean section.Two groups of patients will be studied separately. Patients with BMI greater than or equal to 30 will be included in the obese group, also denominated study group. Patients with BMI less than 25 will be included in the normal weight group, also denominated control group. BMI will be calculated based on the patient's pre-pregnancy weight. For each group, the up-down sequential allocation method based on the Narayana rule will be used to find the minimum effective dose of intrathecal hyperbaric bupivacaine 0.75% associated with opioids necessary for satisfactory outcome in 95% of the pregnant women undergoing cesarean section, i.e. ED95.
There are two possible outcomes in our study: a satisfactory outcome is defined if the sensory block reaches at least at T6 and the patient does not complain of any pain or discomfort that requires intraoperative supplemental drugs; an unsatisfactory outcome is defined if the sensory block reaches a level lower than T6 or the patient complains of pain or discomfort that requires intraoperative supplemental drugs. The decision whether or not the supplementation is required will be made exclusively by the patient, and not by the physician in charge.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X5
- Mount Sinai Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Obese group: All pregnant women at term (over 37 weeks) scheduled for elective Cesarean section, with pre-pregnancy BMI greater than 30
- Normal weight group: All pregnant women at term (over 37 weeks) scheduled for elective Cesarean section, with pre-pregnancy BMI less than 25.
Exclusion Criteria:
- Patient's refusal.
- Patients with any absolute or relative contraindication for spinal/epidural anesthesia.
- Patients with BMI between 25 and 30.
- Patients with more than one fetus.
- Patients unable to communicate in English effectively.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary outcome will be the success/failure of the block. Success meaning a sensory block level at least at T6 within 15 minutes after intrathecal injection and no requirement of any supplemental analgesic by the patient throughout the CS.
Time Frame: 15 minutes
|
15 minutes
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Upper level of sensory blockage determined by the pinprick at midaxillary line
Time Frame: 60 minutes
|
60 minutes
|
|
VAPS during surgery
Time Frame: 60 minutes
|
60 minutes
|
|
Dose of lidocaine 2% required as supplementation
Time Frame: 60 minutes
|
60 minutes
|
|
Dose of IV fentanyl or ketamine required as supplementation
Time Frame: 60 minutes
|
60 minutes
|
|
Conversion to general anesthesia
Time Frame: 60 minutes
|
60 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jose CA Carvalho, MD PhD, Department of Anesthesia and Pain Management, Mount Sinai Hospital, University of Toronto
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Obesity
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Analgesics, Opioid
- Narcotics
- Adjuvants, Anesthesia
- Anesthetics, Local
- Fentanyl
- Bupivacaine
- Morphine
Other Study ID Numbers
- 06-02
- 06-0206-E
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.